美国肺疾病患者临终住院费用分析
该研究基于2009至2019年美国全国住院患者样本数据,纳入18至74岁因肺疾病住院的成人,排除有肺移植史者,分析临终住院费用及趋势。结果显示,109,924例(4.1%)肺疾病住院发生院内死亡,阻塞性肺疾病占住院的94.1%和院内死亡的88.1%。临终住院平均费用为29,981美元,诊断和操作使用导致费用差异很大;接受更多操作的年轻患者住院费用最高。机械通气、体外膜氧合和透析的使用在研究期间显著增加,医院转院率上升,且转院增加在导致院内死亡的住院中比例更大。
要点
- 109,924例(4.1%)肺疾病住院发生院内死亡,其中阻塞性肺疾病占住院的94.1%和院内死亡的88.1%。
- 临终住院平均费用为29,981美元,费用因诊断和操作使用不同而差异很大。
- 接受更多操作的年轻患者住院费用最高,机械通气在最昂贵住院中占干预的最大比例。
- 研究期间机械通气、体外膜氧合和透析的使用显著增加,医院转院率上升且院内死亡住院中转院增加比例更大。
适用人群与场景
- 18至74岁、2009至2019年成本与利用项目全国住院患者样本中因肺疾病住院的成人。
- 排除有肺移植史者。
研究设计与关键结果
- 研究类型为基于成本与利用项目全国住院患者样本2009至2019年数据的分析,纳入18至74岁因肺疾病住院的成人,排除有肺移植史者。
- 109,924例(4.1%)肺疾病住院发生院内死亡。
- 阻塞性肺疾病占住院的94.1%和院内死亡的88.1%。
- 临终住院平均费用为29,981美元,费用因诊断和操作使用不同而差异很大。
- 接受更多操作的年轻患者住院费用最高;在最昂贵的住院中,机械通气占干预的最大比例。
- 研究期间机械通气、体外膜氧合和透析的使用显著增加。
- 医院转院率上升,且转院增加在导致院内死亡的住院中比例更大。
证据类型、等级与局限
- 证据类型:基于全国住院患者样本数据的分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,临终住院期间产生的费用因人而异,但构成显著的医疗保健成本,对于接受肺移植的特定人群,这些费用是可以避免的;这些费用应纳入肺移植成本效果研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Lung transplantation is a lifesaving intervention for people with advanced lung disease, but it is costly and resource-intensive. To investigate the cost-effectiveness of lung transplantation as a treatment option in pulmonary disease, we must understand costs attributable to end-of-life hospitalizations for end-stage lung disease.
RESEARCH QUESTION: What are the costs associated with end-of-life hospitalizations for people with pulmonary disease, and how have these trends changed over time?
STUDY DESIGN AND METHODS: Adults aged 18 to 74 years with hospitalization data in the Cost and Utilization Project National Inpatient Sample data from 2009 to 2019 with a pulmonary disease admission were included in this analysis. Those with a history of lung transplantation were excluded. International Classification of Diseases codes were used to identify pulmonary disease admissions, complications, and procedures and interventions. Total charges were calculated for hospitalizations and stratified by patient status at time of discharge. Trends in charges over time were assessed by demographic and hospital factors.
RESULTS: One hundred nine thousand nine hundred twenty-four (4.1%) hospital admissions for pulmonary disease resulted in in-hospital mortality. Those with obstructive lung disease accounted for 94.1% of hospitalizations and 88.1% cases of in-hospital mortality. Estimated costs for end-of-life hospitalizations were $29,981 on average with wide variation in cost by diagnosis and procedure utilization. Inpatient costs were highest for younger people who received more procedures. Among the most expensive admissions, mechanical ventilation accounted for the greatest proportion of interventions. Significant increases in the use of mechanical ventilation, extracorporeal membrane oxygenation, and dialysis occurred over the time period. The rate of hospital transfers increased with a proportionately greater increase across admissions resulting in in-hospital mortality.
INTERPRETATION: Costs accrued during end-of-life hospitalizations vary across people but represent a significant health care cost that can be averted for selected people who undergo lung transplantation. These costs should be considered in studies of cost-effectiveness in lung transplantation.
参考来源
- Lehr CJ, Dewey E, Udeh B, et al. Costs of End-of-Life Hospitalizations in the United States for People With Pulmonary Diseases. Chest. 2024. PMID: 38224779. doi:10.1016/j.chest.2024.01.022
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。